Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
Rocks, do you have a link to the peer review?
BB
It is an amendment due to:
‘The Company did not include the financial statements including the Interim Results for the Six Months Ended 30 June 2021 in the Original Form 6-K and is furnishing them in this Amendment No. 1.‘
BB
A new low never before seen on the Nasdaq for TLSA - $0.59 (21p in old money) - Accustem could well be worth more than TLSA if it ever lists.
BB
Majority of the drop appears sector wide if you compare the likes of TLSA/TILS.
SO selling won't help with the current depression in the Pharma research sector.
BB
Good post Wigscoff88. I doubled up here Friday PM - Looks like a risk v reward I feel is worth taking, with the pipeline 4d have
BB
JB65
the comment was based more around Foralumab and the historic timeline put out in the coverage shown here:
https://scr.zacks.com/news/news-details/2021/TLSA-In-a-Tizzy-About-Tiziana-article/default.aspx
A bit behind the curve now, but what else can we do, apart from buy low, hoping for success in the coming years.
BB
Until they are listed on the Nasdaq (Expected Q1, I believe??) you cannot trade them as most brokers do not allow trading on the OTC pinks, which is where they are currently traded by those lucky US holders. UK shareholders have been unfairly treated by the TILS/TLSA actions wrt to changing Markets and the Demerger of Accustem and they appear to be unconcerned with the results of their actions on Shareholders. At 25p you reap what you sow!
Having said that, people buying in now will probably multibag with the current SP.
BB
SJ1
4D has SO selling down itr of 10% of the stock if he clears totally. Tils are now buying back stock - itr of 6% at these prices. So that could effect it further.
BB
PS. I'm buying 4d as they are both 70% down over 12 months
30 Business days from 6th Jan = 17th Feb 22
180 Calendar days = Mid August 22 (Q3)
BB
'How long can a stock be under a dollar Nasdaq?
If a company trades for 30 consecutive business days below the $1.00 minimum closing bid price requirement, Nasdaq will send a deficiency notice to the company, advising that it has been afforded a "compliance period" of 180 calendar days to regain compliance with the applicable requirements.'
There are also further options & TLSA is listed on the Nasdaq Global Market. See link:
https://listingcenter.nasdaq.com/ViewPDF.aspx?Material_Search.aspx?mcd=LQ&cid=14&years=2016,2015,2014,2016,2015,2014,2013,2012,2011,2010,2009,2008,2007,2006,2005,2004,2003,2002&sub_cid=76&searchkeywords=&exactsearchddvalue=1&Print=N&materials=0&popularfl
I hope this prevents false information getting spouted.
BB
Isthisawinner - Possibly!
1. Consolidation - We still have the same % holding.
2. GC - Will dilute his holding to F...k, but will probably buy in the fund raise.
3. The price that they raise funds at is normally hit, so we could buy at that level as well.
I believe they are notified after 30 days of being below $1 and have a reasonable time frame to rectify the low SP.
BB
i don't think the company are manipulating the SP south. It's happened with out releasing any bad news for the last 12 months.
BB
I hope so. They may be able to buy back 8% of the shares in issue. It's around 6.5% now. It shold give some support to the SP.
BB
The market isn’t interested in what they have to say. It wants action/results. Saying that, I may buy some later on in Feb.
BB
Repeat your last
Say again , over!
BB
Trials or no trials, this hasn’t changed the outcome for many biotechs. Over 12 months many are 60-80% down.
Why would anyone invest until the trend changes. Hindsight trading is easy. Unfortunately I invested here to early. Start to build 4d now though.
BB
SJ1
The filing states:
This amendment would allow for the investigation of a broader patient population as well as a shorter dosing period. Previously, Tiziana had submitted an IND to conduct a Phase 1b study in moderate-to-severe active Crohn’s Disease patients to evaluate safety of enteric-coated foralumab capsules administered orally once daily for 14 days as an inpatient study in the hospital or CRU with safety monitoring, for which the FDA issued a ‘Study May Proceed letter’.
‘Study may proceed later’ - Is this why they’ve amended the original. Will they carryout the original IND afterwards?
BB
I think they will notify via SEC filing on Successful application with no pick ups from the FDA.
'Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.'
https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
The presentation also shows the market cap as of: 20/12/21. Was this the time it went to press?
Q1/Q2 will be interesting and hopefully the start of the next rise back to £1 in old money. Only a 330% increase from here! 8 weeks of Q1 left.
BB
Bradders64
Mine still show in my account as 30,000 accustem, which matches my TILS holding in Oct/Nov 20. They have not yet been consolidated or given any value. This will occur when they list on the Nasdaq?????
I cant see how you've ended up with 89. As I see it the 4000 shares for you, which will become 200 after consolidation.
BB
Approx $40m in cash. Where did that come from?
Q1 & Q2 has a bit of news to offer that may be significant on the MS data front.
Will it be on time? Who knows, but I’ll hang around.
GLA
BB